ClinicalTrials.gov
public full text
Public Domain
Enhancing the Natriuretic Peptide System in HFpEF
The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Changes in Natriuretic Peptide Levels and Subsequent Kidney Function Decline in SPRINT#1079037
- Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction#858272
- The Correlation Between B-type Natriuretic Peptide (BNP) and Global End Diastolic Volume#980012
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients#903668
- Losartan in Decompensated Heart Failure#1104045
Record · ID 916031
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive